Wednesday, May 24, 2017 9:14:42 AM
The strategy used - explained numerous times - is to hold all the shares bought at the cheapest level in the portfolio for when the stock reaches or exceeds the pps it should be at, whilst continuing to add at every level where the impatient sell or are duped by misinformation nonsense / games / any other factor to sell. I then manage the inventory of shares as market conditions allow. Every single share will earn a significant profit and it is irrelevant to me how long I have to wait on a stock like $DIGX that is a no-brainer and a proven, multiple run per year, repeat winner.
The fact is that the vast majority of shares yesterday were traded at the ask price of .0005. It is not "dumping" when someone hits the ask price repeatedly. It is also not a random paint up when somebody makes a 3M buy at .0006.
Also, there were only around 14M shares traded at .0004. 3 small paint downs of around 400K - including one at .00045 - which then panicked someone into selling 11M almost certainly for a loss - then another 999,999 in the closing minutes.
7M of those shares came to me as I'm always ahead of those that try to manipulate the market with scaremongering. I have GTC orders at every level - some hidden AON. I also added more .0005s in the last 2 days. I'm quite happy to accumulate 100M shares of $DIGX. There is a big difference between someone claiming $DIGX will touch a particular price and anyone actually getting a significant quantity of shares at that price - I stopped people getting any meaningful amount of .0002s throughout 2017 so far and I expect to continue.
There is no dilution - the share structure has been reduced.
There is no convertible debt.
The selling of shares by those entitled to reimbursement for executive services is strictly limited - as fully detailed in the filings - and easy enough (albeit frustrating at times) to trade around.
I'm not going to continue correcting nonsense - good luck to everyone.
Detailed play-by-play analysis will continue on the main board.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM